Shots:

• The CHMP has granted positive opinion to Keytruda + pemetrexed & Pt-based CT as a 1L treatment of adults with unresectable non-epithelioid MPM, with the EC’s decision anticipated in Q4’24. The regimen was approved across the US in Sep 2024 for the same
• The opinion was based on the P-II/III (IND.227/KEYNOTE-483) study assessing Keytruda + CT vs CT alone, showing improved OS
• Study depicted a reduction in the death risk by 21%, with mOS of 17.3 vs 16.1mos., significantly improved PFS, with mPFS of 7.1mos. in both the arms and ORR of 52% vs 29%

Ref: Merck | Image: Merck

Related News:-  Merck Reports EC’s Approval of Keytruda for Two New Indications in Gynecologic Cancers

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com